Table 5

Risk of breast cancer associated with lipid-adjusted serum levels of DDE

Serum level (ppb)Cases (n = 475)aControls (n = 502)aORb (95% CI)ORc (95% CI)
All subjects
<295.01391661.001.00
295.0–660.01571661.09 (0.79–1.50)1.05 (0.76–1.47)
>660.01791701.11 (0.80–1.54)0.96 (0.67–1.36)
P for trend0.420.58
Parous women who ever breast fed
<295.070871.001.00
295.0–660.048650.88 (0.54–1.45)0.87 (0.51–1.49)
>660.056531.14 (0.67–1.93)1.07 (0.60–1.93)
P for trend0.450.85
Parous women who never breast fedd
<295.053581.001.00
295.0–660.083691.28 (0.78–2.10)1.19 (0.71–2.01)
>660.0103911.11 (0.68–1.80)0.96 (0.57–1.62)
P for trend0.850.59
Nulliparous womene
<295.016211.001.00
295.0–660.024311.05 (0.45–2.46)0.45 (0.15–1.28)
>660.020261.20 (0.46–3.12)0.59 (0.16–2.16)
P for trend0.300.74
  • a Total number of cases or controls.

  • b Adjusted only for age (<47, 47–52, 53–63,≥ 64 years).

  • c Additional adjustments include BMI (<21, 21–24.9, ≥25 kg/m2), age at menarche (<13, 13–14, ≥15 years), lifetime months of lactation (0, 1–10, ≥11), age at first full-term pregnancy (nulliparous, <20, 20–25, ≥26 years), number of live births (0, 1–3, ≥4), lifetime months of hormone replacement therapy (0, 1–71, ≥72), dietary fat intake in g/day (<46, 46–71,≥ 72, unknown), family breast cancer history, income (<$20,000, $20,000–24,999, ≥$25,000, or unknown), race (white, black, and other), and study site.

  • d Not adjusted for lactation.

  • e Not adjusted for lactation, age at first full-term pregnancy, and number of live births.